Nu Skin Enterprises, Inc. (NYSE: NUS) today announced that it has closed the transaction to acquire LifeGen Technologies, LLC, a genomics company based in Madison, Wisconsin for $11.7 million. The Nu Skin purchase will result in the transfer of substantially all of the assets of LifeGen to Nu Skin, including its proprietary tissue bank and gene expression database, patents and other intellectual property related to anti-aging gene research. The company also initiated new research and development contracts, consulting and non-competition agreements with LifeGen co-founders, Richard Weindruch, Ph.D., and Tomas Prolla, Ph.D., who will both manage and provide scientific leadership at the Madison-based research facility and continue to serve on the Nu Skin Anti-aging Scientific Advisory Board. “We are pleased to have completed the acquisition of LifeGen,” said Dr. Joseph Chang, Nu Skin’s chief scientific officer. “We believe the acquisition significantly enhances ...
Comments
Post a Comment